|
August 4-6, 2009
(August 4 pre-conference workshop*, August 5-6 main conference)
Innovations in Discovery Science, Translational Research and Cancer Clinical Trials
The failure rate for cancer drug approvals is high relative to other therapeutic areas because of poor preclinical models of human cancer, challenges in demonstrating efficacy in the clinic, and the complexity of clinical trial design for cancer drugs. Bridging the gap between discovery science, clinical science and clinical trial design to improve translation from preclinical to clinical is crucial to increase cancer drug approval rates. This conference will explore many of the new frontiers in cancer drug development that companies are exploring to fill the innovation gap including new advances in cancer stem cell research and emerging data from combinations of molecular targeted cancer agents that are showing promise. Practical examples of the development of biomarkers and companion diagnostics to inform cancer drug development strategies and to stratify and select patient populations for cancer clinical trials will also be presented including a discussion of the regulatory pathway and FDA position relative to cancer drug development.
Why You Should Attend:
- Listen to the latest information from companies developing therapeutics based on cancer stem cell research
- Learn about the regulatory pathway and FDA position on biomarkers and companion diagnostics for cancer
- Evaluate data emerging from exciting cancer targets/pathways and cancer epigenetic studies
- Hear the latest clinical results of combinations of molecular targeted cancer agents
Confirmed Speakers and Sessions
(As of March 13, 2009)
Pre-Conference Workshop
Biomarkers and Companion Diagnostics for Cancer Therapy
- Towia A. Libermann, Associate Professor of Medicine, Beth Israel Deaconess Medical Center and Director, BIDMC Genomics and Proteomics Center
- Murray O. Robinson, Ph.D., Senior Vice President, Oncology, AVEO Pharmaceuticals, Inc.
- Scott D. Patterson, Ph.D., Executive Director, Medical Sciences, Amgen, Inc.
- Nicholas C. Dracopoli, Ph.D., Vice President, Biomarkers, Centocor R&D, Johnson & Johnson
- John C Bloom, Ph.D., Executive Director, Diagnostic and Experimental Medicine, Eli Lilly and Company
- Richard A. Bender, M.D., Vice President and Chief Medical Officer, Agendia BV
Main Conference
Understanding and Exploiting the Role of Cancer Stem Cells in Drug Development
- Timothy Hoey, Ph.D., Vice President, Cancer Biology, OncoMed Pharmaceuticals, Inc.
- Jeff Jackson, Ph.D., Director, Cancer Stem Cell DPU, Oncology R&D, GlaxoSmithKline
- Jenny P. Mather, M.D., Ph.D., Senior Vice President, Cancer Stem Cell Research, MacroGenics, Inc. West
- Ivan Bergstein, M.D., CEO, Stemline Therapeutics, Inc.
- Chia Portera, M.D., Ph.D., Assistant Medical Director, Exploratory Clinical Development, Genentech BioOncology
- Lyuba Varticovski, Staff Clinician, National Cancer Institute
New Approaches for Targeting Cancer
- Sandra S. McAllister, Ph.D., Postdoctoral Associate, Robert Weinberg Laboratory, Whitehead Institute for Biomedical Research
- Jon Oliner, M.D., Ph.D., Scientific Director, Oncology Research, Amgen, Inc.
- Patrick Trojer, Ph.D., Senior Scientist, Constellation Pharmaceuticals
- Hao Zhu, M.D., Post-Doctoral Fellow, Department of Hematology/Oncology, The George Q. Daley Laboratory, Dana Farber Cancer Institute and Children's Hospital of Boston
- Heidi Greulich, Ph.D., Instructor, Dana Farber Cancer Institute and Visiting Scientist, The Broad Institute of MIT and Harvard
Point-Counterpoint Debate and Discussion: Innovation Starvation in Oncology Drug Development: Implications for R&D Strategies
- John Herrmann, Ph.D., Executive Director, Search & Evaluation (Oncology), EMD Serono (U.S. Division of Merck Serono)
- Daniel S. Pereira, Ph.D., Vice President, Head of Research, Pharma Research Toronto, Hoffmann-La Roche Ltd., Canada
Combination Cancer Therapies and Multi-Targeting Strategies for Novel Therapeutics
- Kenneth C. Anderson, M.D, Chief, Division of Hematologic Neoplasia, Dana-Farber Cancer Institute and Kraft Family Professor of Medicine, Harvard Medical School
- Helen Chen, M.D., Associate Branch Chief, Cancer Therapy Evaluation Program, National Cancer Institute
- Asha Das, M.D., Medical Director, BioOncology, Genentech
- Daniel Passeri, President and CEO, Curis, Inc.
Strategic Discussion Group: Are Targeted Therapies Better than Non-Targeted Therapies?
- William N. Hait, M.D., Ph.D., Senior Vice President, Worldwide Head Oncology/Hematology R&D, Ortho Biotech Oncology R&D, The Johnson & Johnson Family of Companies
Translational Strategies for Cancer Drug Development
- Herbert A. Fritsche, Ph.D., Professor and Chief of Clinical Chemistry, The University of Texas M. D. Anderson Cancer Center
- Daniel B. Tumas, Ph.D., Director, Drug Safety Evaluation, Gilead Sciences, Inc.
- Kevin Webster, Ph.D., Executive Director, Cancer and Infection Drug Discovery, AstraZeneca R&D (Invited)
- Chris H. Takimoto, M.D., Ph.D., Senior Director, Translational Medicine, Ortho Biotech Oncology R&D/Centocor R&D, Inc
Scientific Advisory Board
Helen Chen, M.D., Associate Branch Chief, Cancer Therapy Evaluation Program, National Cancer Institute
Kevin P. Foley, Ph.D., Director of In Vivo Pharmacology, Synta Pharmaceuticals Corp.
William Hait, M.D., Ph.D., Senior Vice President, Worldwide Head, Oncology/Hematology R&D, Ortho Biotech Oncology - A J&J Co.
John Herrmann, Ph.D., Executive Director, Search & Evaluation (Oncology), EMD Serono (U.S. Division of Merck Serono)
Julia Y. Ljubimova, M.D., Ph.D., Director of Drug Delivery and Nanomedicine, Department of Neurosurgery, Cedars-Sinai Medical Center
John Newcomb, Ph.D., Director, Research, Hematology/Oncology Research, Amgen, Inc.
Lyuba Varticovski, Staff Clinician, National Cancer Institute
|
